Kura Oncology is a clinical-stage biopharmaceutical company dedicated to advancing precision medicines for cancer treatment. The company focuses on developing small molecule drug candidates that target specific cancer signaling pathways. Notably, Kura's lead candidate, ziftomenib, has received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory NPM1-mutant acute myeloid leukemia. With a commitment to innovation and a patient-centered approach, Kura Oncology fosters a diverse and collaborative work environment, aiming to make a significant impact in the field of oncology.